Inactief instrument

Andere talen Can-Fite BioPharma Ltd. TEL AVIV STOCK EXCHANGE

Aandelen

CANF

IL0010944739

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	25/04
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	16/04
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15/04
Can Fite BioPharma : Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15/04
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	03/04
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	03/04
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	03/04
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV	01/04
Can Fite BioPharma : 20F FOR 2023	28/03
Can-Fite Biopharma Ltd. Announces Clinical Update	28/03
Can-Fite Reports 2023 Financial Results and Clinical Update	28/03
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	11/03
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	11/03
CAN-FITE BROADENS ITS STRONG INTELLECTUAL PROPERTY FOR NASH, RECEIVED PATENT ALLOWANCE IN CANADA	29/02
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	28/02
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	28/02
CAN-FITE, TOP SCIENTIFIC JOURNAL PUBLISHED POSITIVE DATA FROM THE COMFORT-1 PHASE III PSORIASIS STUDY	30/01
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	30/01
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	30/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Can-Fite BioPharma Ltd. TEL AVIV STOCK EXCHANGE

Aandelen

CANF

IL0010944739

Andere talen

Filters